Cancer .2009;115(7):1531–1543.

PMC free article]PubMed] Google Scholar]

Mirabello L., Troisi R.J., Savage S.A. Osteosarcoma incidence và survival rage calculator in years
es from 1973 bự 2004 : dữ liệu from the Surveillance, Epidemiology, và End Results Program .một .

J Pediatr Hematol Oncol .2008;30(6):425–430.

[PubMed] Google Scholar]Esiashvili N., Goodman M., Marcus R.B., Jr Changes in incidence & survival of Ewing sarcoma patients kết thúc the past tam decades : Surveillance, Epidemiology, và End Results data .2 .

Cancer .2009;115(18):4218–4226.

PMC free article]PubMed] Google Scholar]Ognjanovic S., Linabery A.M., Charbonneau B., Ross J.A. Trends in childhood rhabdomyosarcoma incidence và survival in the United States, 1975 – 2005 .tam .

J Pathol .2009;219(3):294–305.

[PubMed] Google Scholar]Mohseny A.B., Szuhai K., Romeo S. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization và genomic loss of Cdkn2 .bốn .

Cancer Treat Res .2009;152:467–478.

[PubMed] Google Scholar]Gorlick R. Current concepts on the molecular biology of osteosarcoma .5 .

Virchows Arch .2010;456(2):201–217.

[PubMed] Google Scholar]Guillou L., Aurias A. Soft tissue sarcomas with complex genomic profiles .6 .Google Scholar]Folpe A.L., Inwards C.Y. Saunders / Elsevier ; Philadelphia, PA : 2010. Bone & Soft Tissue Pathology .7 .

Cancer .2011;117(8):1731–1735.

[PubMed] Google Scholar]Cesari M., Alberghini M., Vanel D. Periosteal osteosarcoma : a single-institution experience .8 .

Cancer .1990;65(6):1418–1428.

[PubMed] Google Scholar]Kurt A. – M., Unni K.K., McLeod R.A., Pritchard D.J. Low-grade intraosseous osteosarcoma .9 .

J Surg Oncol .2008;97(2):146–149.

[PubMed] Google Scholar]Han I., Oh J.H., Na Y.G., Moon K.C., Kim K.S. Clinical outcome of parosteal osteosarcoma .10 .

J Bone Joint Surg Am .1994;76(3):366–378.

[PubMed] Google Scholar]Okada K., Frassica F.J., Sim F.H., Beabout J.W., Bond J.R., Unni K.K. Parosteal osteosarcoma : a clinicopathological study .11 .

Clin Orthop Relat Res .1991;270:140–148.

[PubMed] Google Scholar]Raymond A.K. Surface osteosarcoma .12 .

Cancer .1996;78(10):2136–2145.

[PubMed] Google Scholar]Sheth D.S., Yasko A.W., Raymond A.K. Conventional và dedifferentiated parosteal osteosarcoma : diagnosis, treatment, & outcome .13 .

Clin Orthop Relat Res .2006;453:314–317.

[PubMed] Google Scholar]Rose P.S., Dickey I.D., Wenger D.E., Unni K.K., Sim F.H. Periosteal osteosarcoma : long-term outcome & risk of late recurrence .14 .Google Scholar]Weiss S.W., Goldblum J.R. 5 th ed. Mosby Elsevier ; Philadelphia, PA : 2008. Enzinger và Weiss ‘ Soft Tissue Tumors .15 .

Am J Surg Pathol .2005;29(8):1025–1033.

[PubMed] Google Scholar]Folpe A.L., Goldblum J.R., Rubin B.P. Morphologic & immunophenotypic diversity in Ewing family tumors : a study of 66 genetically confirmed cases .16 .

Expert Rev Mol Diagn .2008;8(1):97–105.

[PubMed] Google Scholar]Khoury J.D. Ewing sarcoma family of tumors : a Model for the mới nhất era of integrated laboratory diagnostics .17 .

J Clin Oncol .2010;28(12):1982–1988.

[PubMed] Google Scholar]Le Deley M.C., Delattre O., Schaefer K.L. Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma / peripheral primitive neuroectodermal tumor : prospective results from the cooperative Euro-E. W.I.N.G. 99 trial .18 .

J Clin Oncol .2010;28(12):1989–1994.

PMC free article]PubMed] Google Scholar]van Doorninck J.A., Ji L., Schaub B. Current treatment protocols have eliminated the prognostic advantage of type một fusions in Ewing sarcoma : a báo cáo from the Children’s Oncology Group .19 .

Mod Pathol .2001;14(5):506–514.

[PubMed] Google Scholar]Parham D.M. Pathologic classification of rhabdomyosarcomas và correlations with molecular studies .trăng tròn .

Mod Pathol .2001;14(10):1068.

[Mod Pathol. 2001;14:506-514] [Google Scholar]Parham D.M. Correspondence re : Parham DM : Pathologic classification of rhabdomyosarcomas & correlations with molecular studies. [ Mod Pathol. 2001 ; 14 : 506 – 514 ] [ PubMed21 .

Virchows Arch .2005;446(1):64–67.

[PubMed] Google Scholar]Croes R., Debiec-Rychter M., Cokelaere K., De Vos R., Hagemeijer A., Sciot R. Adult sclerosing rhabdomyosarcoma : cytogenetic liên kết with embryonal rhabdomyosarcoma .22 .

Am J Pathol .2000;156(2):399–408.

PMC free article]PubMed] Google Scholar]Dias Phường, Chen B., Dilday B. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass .23 .

Mod Pathol .2008;21(7):795–806.

[PubMed] Google Scholar]Bahrami A., Gown A.M., Baird G.S., Hicks M.J., Folpe A.L. Aberrant expression of epithelial & neuroendocrine markers in alveolar rhabdomyosarcoma : a potentially serious diagnostic pitfall .24 .

Genes Chromosomes Cancer .2010;49(3):224–236.

PMC free article]PubMed] Google Scholar]Sumegi J., Streblow R., Frayer R.W. Recurrent t ( 2 ; 2 ) & t ( 2 ; 8 ) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 lớn members of the nuclear receptor transcriptional coactivator family .25 .

Clin Transl Oncol .2007;9(7):415–419.

[PubMed] Google Scholar]Gallego Melcón S., Sánchez de Toledo Codina J. Molecular biology of rhabdomyosarcoma .26 .

J Clin Oncol .2010;28(7):1240–1246.

PMC free article]PubMed] Google Scholar]Davicioni E., Anderson J.R., Buckley J.D., Meyer W.H., Triche T.J. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas : a báo cáo from the Children’s Oncology Group .27 .

J Bone Joint Surg Am .1996;78(5):656–663.

[PubMed] Google Scholar]Mankin H.J., Mankin C.J., Simon M.A. The hazards of biopsy, revisited : for the members of the Musculoskeletal Tumor Society .28 .

J Clin Oncol .2007;25(34):5435–5441.

[PubMed] Google Scholar]Völker T., Denecke T., Steffen I. Positron emission tomography for staging of pediatric sarcoma patients : results of a prospective multicenter trial .29 .

J Clin Oncol .2005;23(34):8828–8834.

[PubMed] Google Scholar]Hawkins D.S., Schuetze S.M., Butrynski J.E. [ 18F ] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors .30 .

Cancer .2009;115(15):3519–3525.

PMC free article]PubMed] Google Scholar]Hawkins D.S., Conrad E.U., III, Butrynski J.E., Schuetze S.M., Eary J.F. [ F-18 ] – fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children & young adults .31 .

Cancer Treat Res .2009;152:289–308.

[PubMed] Google Scholar]Bielack S., Jürgens H., Jundt G. Osteosarcoma : the COSS experience .32 .

J Clin Oncol .2008;26(4):633–638.

[PubMed] Google Scholar]Meyers P.A., Schwartz C.L., Krailo M.D., Children’s Oncology Group Osteosarcoma : the addition of muramyl tripeptide Khủng chemotherapy improves overall survival — a báo cáo from the Children’s Oncology Group .33 .

J Bone Joint Surg Br .2006;88(8):1071–1075.

[PubMed] Google Scholar]Bacci G., Fabbri N., Balladelli A., Forni C., Palmerini E., Picci P. Treatment & prognosis for synchronous multifocal osteosarcoma in 42 patients .34 .

J Clin Oncol .2003;21(10):2011–2018.

[PubMed] Google Scholar]Kager L., Zoubek A., Pötschger U., Cooperative German-Austrian-Swiss Osteosarcoma Study Group Primary metastatic osteosarcoma : presentation và outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols .35 .

J Clin Oncol .2002;đôi mươi(3):776–790.

[PubMed] Google Scholar]Bielack S.S., Kempf-Bielack B., Delling G. Prognostic factors in high-grade osteosarcoma of the extremities or trunk : an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols .36 .

J Clin Oncol .2000;18(24):4016–4027.

[PubMed] Google Scholar]Bacci G., Ferrari S., Bertoni F. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according Khủng the Istituto Ortopedico Rizzoli / Osteosarcoma-2 Protocol : an updated báo cáo .37 .Euramos I Trial. http://www.ctu.mrc.ac.uk/euramos/euramos_i_trial.asp The European và American Osteosarcoma Study Group Web site. Accessed April bốn, 2012 .38 .National Cancer Institute Phase II study of chemotherapy with or without trastuzumab ( Herceptin ® ) in patients with metastatic osteosarcoma. http://www.cancer.gov/clinicaltrials/search/view?cdrid=68882&version=HealthProfessional&protocolsearchid=9547220 National Cancer Institute Web site. Accessed April 9, 2012 .39 .

Cancer .2011;117(8):1736–1744.

PMC free article]PubMed] Google Scholar]Meyers P.A., Healey J.H., Chou A.J. Addition of pamidronate béo chemotherapy for the treatment of osteosarcoma .40 .National Cancer Institute Pilot study of zoledronic acid in combination with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma : National Cancer Institute Web site. http://www.cancer.gov/clinicaltrials/search/view?cdrid=612613&version=HealthProfessional&protocolsearchid=9547220 Accessed April 9, 2012 .41 .

Clin Orthop Relat Res .2010;468(11):2854–2859.

PMC free article]PubMed] Google Scholar]Ayerza M.A., Farfalli G.L., Aponte-Tinao L., Muscolo D.L. Does increased rate of limb-sparing surgery affect survival in osteosarcoma ?42 .

Clin Orthop Relat Res .2003;415:72–81.

[PubMed] Google Scholar]Neel M.D., Wilkins R.M., Rao B.N., Kelly C.M. Early multicenter experience with a noninvasive expandable prosthesis .43 .

Clin Orthop Relat Res .2008;466(8):1856–1862.

PMC free article]PubMed] Google Scholar]Musculo D.L., Ayerza M.A., Aponte-Tinao L., Farfalli G.L. Allograft reconstruction after sarcoma excision in children younger than 10 years old .44 .

J Bone Joint Surg Br .2009;91(10):1366–1372.

[PubMed] Google Scholar]Abed Y.Y., Beltrami G., Campanacci D.A., Innocenti M., Scoccianti G., Capanna R. Biological reconstruction after resection of bone tumours around the knee : long-term follow-up .45 .

Clin Orthop Relat Res .2009;467(11):2792–2799.

PMC free article]PubMed] Google Scholar]Farfalli G.L., Boland P.J., Morris C.D., Athanasian E.A., Healey J.H. Early equivalence of uncemented press-fit & Compress femoral fixation .46 .

J Bone Joint Surg Br .1994;76(1):127–132.

[PubMed] Google Scholar]Cañadell J., Forriol F., Cara J.A. Removal of metaphyseal bone tumours with preservation of the epiphysis : physeal distraction before excision .47 .Google Scholar]Teplyakov V., Solovyev J., Aliev M. Transosseous osteosynthesis by Ilizarov in the treatment of patients with primary malignant tumours of long bones. Proceedings of the 17 th Annual Meeting of the European Musculoskeletal Oncology Society ; June 9-11, 2004. Oslo, Norway .48 .

Acta Orthop Scand .2002;73(1):85–88.

[PubMed] Google Scholar]Rödl R.W., Pohlmann U., Gosheger G., Lindner N.J., Winkelmann W. Rotationplasty — unique of life after 10 years in 22 patients .49 .

Clin Orthop Relat Res .2003;415:52–58.

[PubMed] Google Scholar]Fuchs B., Kotajarvi B.R., Kaufman K.R., Sim F.H. Functional outcome of patients with rotationplasty about the knee .50 .

Prosthet Orthot Int .2010;34(4):362–377.

[published correction appears in Prosthet Orthot Int. 2011;35(1):113] [Google Scholar]Highsmith M.J., Kahle J.T., Bongiorni D.R., Sutton B.S., Groer S., Kaufman K.R. Safety, energy efficiency, & cost efficacy of the C-Leg for transfemoral amputees : a nhận xét of the literature. [ published correction appears in Prosthet Orthot Int. 2011 ; 35 ( một ) : 113 ] [ PubMed51 .

Clin Orthop Relat Res .2002;397:12–18.

[PubMed] Google Scholar]Fuchs B., Yaszemski M.J., Sim F.H. Combined posterior pelvis & lumbar spine resection for sarcoma .52 .

Cancer .2011;117(19):4522–4530.

PMC free article]PubMed] Google Scholar]Ciernik I.F., Niemierko A., Harmon D.C. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma .53 .

BMC Cancer .2010;10:96.

PMC free article]PubMed] Google Scholar]Blattmann C., Oertel S., Schulz-Ertner D. Non-randomized therapy trial bự determine the safety & efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma .54 .

Int J Radiat Oncol Biol Phys .2012;82(5):2125–2131.

[PubMed] Google Scholar]Jingu K., Tsujii H., Mizoe J.E., Organizing Committee for the Working Group for Head-and-Neck Cancer Carbon ion radiation therapy improves the prognosis of unresectable adult bone & soft-tissue sarcoma of the head & neck .55 .

J Natl Med Assoc .2007;99(7):785–794.

PMC free article]PubMed] Google Scholar]Hillegonds D.J., Franklin S., Shelton D.K., Vijayakumar S., Vijayakumar V. The management of painful bone metastases with an emphasis on radionuclide therapy .56 .

Cancer Treat Res .2009;152:147–164.

[PubMed] Google Scholar]Schwarz R., Bruland O., Cassoni A., Schomberg P., Bielack S. The role of radiotherapy in oseosarcoma .57 .

N Engl J Med .2003;348(8):694–701.

[PubMed] Google Scholar]Grier H.E., Krailo M.D., Tarbell N.J. Addition of ifosfamide & etoposide mập standard chemotherapy for Ewing’s sarcoma & primitive neuroectodermal tumor of bone .58 .

J Clin Oncol .2009;27(15):2536–2541.

PMC free article]PubMed] Google Scholar]Granowetter L., Womer R., Devidas M. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors : a Children’s Oncology Group Study .59 .

J Clin Oncol .2008;26(15, suppl):10504.

[abstract] Google Scholar]Womer R.B., West D.C., Krailo M.D., Dickman P.S., Pawel B., Children’s Oncology Group AEWS0031 Committee Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors ( ESFT ) [ abstract ]60 .National Cancer Institute Phase III randomized study of adding vincristine sulfate, topotecan hydrochloride, & cyclophosphamide bự standard chemotherapy in patients with non-metastatic extracranial Ewing sarcoma. http://www.cancer.gov/clinicaltrials/search/view?cdrid=687639&version=HealthProfessional&protocolsearchid=9547232 National Cancer Institute Web site .61 .National Cancer Institute Phase III randomized study of standard induction chemotherapy comprising vincristine, dactinomycin, ifosfamide, và etoposide followed by consolidation chemotherapy comprising vincristine, dactinomycin, và ifosfamide versus high-dose busulfan và melphalan followed by autologous peripheral blood stem cell tư vấn with or without radiotherapy & / or surgery in patients with tumor of the Ewing’s family. http://www.cancer.gov/clinicaltrials/search/view?cdrid=68608&version=HealthProfessional&protocolsearchid=9547232 National Cancer Institute Web site. Accessed April 9, 2012 .62 .

Expert Rev Anticancer Ther .2011;11(2):251–262.

[PubMed] Google Scholar]Rosenthal J., Pawlowska A.B. High-dose chemotherapy và stem cell rescue for high-risk Ewing’s family of tumors .63 .

Lancet Oncol .2010;11(2):184–192.

[PubMed] Google Scholar]Balamuth N.J., Womer R.B. Ewing’s sarcoma .64 .

Cancer .2003;98(12):2687–2692.

[PubMed] Google Scholar]Fuchs B., Valenzuela R.G., Inwards C., Sim F.H., Rock M.G. Complications in long-term survivors of Ewing sarcoma .65 .

J Clin Oncol .2009;27(15):2536–2541.

PMC free article]PubMed] Google Scholar]Granowetter L., Womer R., Devidas M. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors : a Children’s Oncology Group Study .66 .

J Surg Oncol .2007;96(1):19–25.

[PubMed] Google Scholar]Donati D., Yin J., Di Bella C. Local & distant control in non-metastatic pelvic Ewing’s sarcoma patients .67 .

J Clin Oncol .2006;24(24):3838–3843.

[PubMed] Google Scholar]Yock T.I., Krailo M., Fryer C.J., Children’s Oncology Group Local control in pelvic Ewing sarcoma : analysis from INT-0091 — a báo cáo from the Children’s Oncology Group .68 .

Cancer .1995;76(8):1388–1397.

[PubMed] Google Scholar]Yang R.S., Eckardt J.J., Eilber F.R. Surgical indications for Ewing’s sarcoma of the pelvis .69 .

J Bone Joint Surg Am .1993;75(10):1457–1465.

[PubMed] Google Scholar]Frassica F.J., Frassica D.A., Pritchard D.J., Schomberg P.J., Wold L.E., Sim F.H. Ewing sarcoma of the pelvis : clinicopathologic features & treatment .70 .

Pediatr Blood Cancer .2004;42(5):465–470.

[PubMed] Google Scholar]Dunst J., Schuck A. Role of radiotherapy in Ewing tumors .71 .

Pediatr Blood Cancer .2011;57(1):169–171.

[PubMed] Google Scholar]Liu A.K., Stinauer M., Albano E., Greffe B., Tello T., Maloney K. Local control of metastatic sites with radiation therapy in metastatic Ewing sarcoma & rhabdomyosarcoma .72 .

Cancer .2010;116(2):443–450.

[PubMed] Google Scholar]Haeusler J., Ranft A., Boelling T. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma ( PDMES )73 .

Expert Rev Anticancer Ther .2005;5(2):283–294.

[PubMed] Google Scholar]Ferrari A., Casanova M. Current chemotherapeutic strategies for rhabdomyosarcoma .74 .

Expert Rev Anticancer Ther .2010;10(8):1285–1301.

[PubMed] Google Scholar]Sultan I., Ferrari A. Selecting multimodal therapy for rhabdomyosarcoma .75 .

J Clin Oncol .2001;19(12):3091–3102.

[PubMed] Google Scholar]Crist W.M., Anderson J.R., Meza J.L., Intergroup Rhabdomyosarcoma Study Group ( IRSG ) Intergroup Rhabdomyosarcoma Study-IV : results for patients with nonmetastatic disease .76 .

J Clin Oncol .2005;23(12):2618–2628.

[PubMed] Google Scholar]Stevens M.C., Rey A., Bouvet N. Treatment of nonmetastatic rhabdomyosarcoma in childhood và adolescence : third study of the International Society of Paediatric Oncology — SIOP Malignant Mesenchymal Tumor 89 .77 .

J Clin Oncol .2011;29(10):1312–1318.

PMC free article]PubMed] Google Scholar]Raney R.B., Walterhouse D.O., Meza J.L. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine và dactinomycin with or without cyclophosphamide & radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma : a báo cáo from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group .78 .

J Clin Oncol .2011;29(15, suppl):9516.

[abstract] Google Scholar]Walterhouse D., Pappo A.S., Meza J.L. Shorter duration therapy that includes vincristine ( V ), dactinomycin ( A ), và lower doses of cyclophosphamide ( C ) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma ( ERMS ) : a báo cáo from the Children’s Oncology Group ( COG ) [ abstract ]79 .

J Clin Oncol .2009;27(31):5182–5188.

PMC free article]PubMed] Google Scholar]Arndt C.A., Stoner J.A., Hawkins D.S. Vincristine, actinomycin, và cyclophosphamide compared with vincristine, actinomycin, và cyclophosphamide alternating with vincristine, topotecan, & cyclophosphamide for intermediate-risk rhabdomyosarcoma : Children’s Oncology Group Study D9803 .80 .National Cancer Institute Phase III randomized study of vincristine, dactinomycin, và cyclophosphamide ( VAC ) versus VAC alternating with vincristine và irinotecan hydrochloride in combination with radiotherapy in patients with newly diagnosed, intermediate-risk rhabdomyosarcoma. http://www.cancer.gov/clinicaltrials/search/view?cdrid=487560&protocolsearchid=9398356&version=healthprofessional National Cancer Institute Web site. Accessed April 9, 2012 .81 .

J Clin Oncol .2008;26(14):2384–2389.

PMC free article]PubMed] Google Scholar]Oberlin O., Rey A., Lyden E. Prognostic factors in metastatic rhabdomyosarcomas : results of a pooled analysis from United States and European cooperative groups .82 .

J Clin Oncol .2004;22(23):4787–4794.

[published correction appears in J Clin Oncol. 2005;23(1):248] [Google Scholar]Carli M., Colombatti R., Oberlin O. European intergroup studies ( MMT4-89 and MMT4-91 ) on childhood metastatic rhabdomyosarcoma : final results & analysis of prognostic factors. [ published correction appears in J Clin Oncol. 2005 ; 23 ( một ) : 248 ] [ PubMed83 .

Eur J Cancer .2009;45(17):3035–3041.

[PubMed] Google Scholar]Bisogno G., Ferrari A., Prete A. Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma .84 .

J Pediatr Hematol Oncol .2001;23(5):272–276.

[PubMed] Google Scholar]Weigel B.J., Breitfeld P.P., Hawkins D., Crist W.M., Baker K.S. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma .85 .

Lancet Oncol .2005;6(2):77–84.

[PubMed] Google Scholar]Stevens M.C. Treatment for childhood rhabdomyosarcoma : the cost of cure .86 .

J Clin Oncol .2005;23(12):2586–2587.

[editorial] [Google Scholar]Donaldson S.S., Anderson J.R. Rhabdomyosarcoma : many similarities, a few philosophical differences. [ editorial ] [ PubMed87 .

Pediatr Blood Cancer .2009;52(4):439–446.

PMC free article]PubMed] Google Scholar]Ritchey M., Ferrer F., Shearer P., Spunt S.L. Late effects on the urinary bladder in patients treated for cancer in childhood : a báo cáo from the Children’s Oncology Group .88 .

Cancer .2011;117(3):625–634.

PMC free article]PubMed] Google Scholar]Nagarajan R., Kamruzzaman A., Ness K.K. Twenty years of follow-up of survivors of childhood osteosarcoma : a báo cáo from the Childhood Cancer Survivor Study .89 .

J Natl Cancer Inst .2010;102(16):1272–1283.

PMC free article]PubMed] Google Scholar]Ginsberg J.P., Goodman P., Leisenring W. Long-term survivors of childhood Ewing sarcoma : báo cáo from the Childhood Cancer Survivor Study .90 .

Pediatr Blood Cancer .2009;53(1):84–89.

[PubMed] Google Scholar]Aksnes L.H., Bauer H.C., Dahl A.A. Health status at long-term follow-up in patients treated for extremity localized Ewing Sarcoma or osteosarcoma : a Scandinavian sarcoma nhóm study .91 .

Pediatr Blood Cancer .2005;44(7):643–653.

[PubMed] Google Scholar]Punyko J.A., Mertens A.C., Gurney J.G. Long-term medical effects of childhood và adolescent rhabdomyosarcoma : a báo cáo from the Childhood Cancer Survivor Study .92 .

J Natl Cancer Inst .2010;102(14):1083–1095.

PMC free article]PubMed] Google Scholar]Friedman D.L., Whitton J., Leisenring W. Subsequent neoplasms in 5 – year survivors of childhood cancer : the Childhood Cancer Survivor Study .93 .

Eur J Cancer .2008;44(7):983–991.

PMC free article]PubMed] Google Scholar]Navid F., Billups C., Liu T., Krasin M.J., Rodriguez-Galindo C. Second cancers in patients with the Ewing sarcoma family of tumours .94 .

Radiat Res .2010;174(6):840–850.

PMC free article]PubMed] Google Scholar]Armstrong G.T., Stovall M., Robison L.L. Long-term effects of radiation exposure among adult survivors of childhood cancer : results from the Childhood Cancer Survivor Study .95 .Children’s Oncology Group Long-term follow-up guidelines for survivors of childhood, adolescent, và young adult cancers. http://www.survivorshipguidelines.org/ Children’s Oncology Group Web site. Accessed April 9, 2012 .96 .

Cancer Res .2005;65(9):3868–3876.

[PubMed] Google Scholar]Scotlandi K., Manara M.C., Nicoletti G. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors .97 .

Cancer Res .2003;63(16):5073–5083.

[PubMed] Google Scholar]Maloney E.K., McLaughlin J.L., Dagdigian N.E. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation .98 .

Pediatr Blood Cancer .2008;50(6):1190–1197.

[PubMed] Google Scholar]Kolb E.A., Gorlick R., Houghton P.J. Initial testing ( stage một ) of a monoclonal antibody ( SCH 717454 ) against the IGF-1 receptor by the Pediatric Preclinical Testing Program .99 .

J Clin Oncol .2011;29(34):4534–4540.

PMC free article]PubMed] Google Scholar]Juergens H., Daw N.C., Geoerger B. Preliminary efficacy of the anti-insulin-like growth factor type một receptor antibody figitumumab in patients with refractory Ewing sarcoma .100 .

J Clin Oncol .2010;28(33):4985–4995.

PMC free article]PubMed] Google Scholar]Maki R.G. Small is beautiful : insulin-like growth factors & their role in growth, development, và cancer .101 .

J Clin Oncol .2011;29(34):4541–4547.

PMC free article]PubMed] Google Scholar]Pappo A.S., Patel S.R., Crowley J. R1507, a monoclonal antibody Khủng the insulin-like growth factor một receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors : results of a phase II Sarcoma Alliance for Research through Collaboration study .102 .

J Clin Oncol .2012;30(1):78–84.

[PubMed] Google Scholar]Chawla S.P., Staddon A.P., Baker L.H. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone và soft tissue sarcomas .103 .

Nat Rev Drug Discov .2004;ba(5):391–400.

[PubMed] Google Scholar]Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery và development of bevacizumab, an anti-VEGF antibody for treating cancer .104 .

Cancer Res .2000;60(22):6253–6258.

[PubMed] Google Scholar]Gerber H.P., Kowalski J., Sherman D., Eberhard D.A., Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth và neovascularization requires blockade of both tumor & host vascular endothelial growth factor .105 .

Pediatr Blood Cancer .2008;50(4):799–805.

[PubMed] Google Scholar]Houghton P.J., Morton C.L., Kolb E.A. Initial testing ( stage một ) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program .106 .

Cancer Res .2009;69(19):7662–7671.

PMC free article]PubMed] Google Scholar]Kurmasheva R.T., Dudkin L., Billups C., Debelenko L.V., Morton C.L., Houghton P.J. The insulin-like growth factor-1 receptor-targeting antibody, CP-751, 871, suppresses tumor-derived VEGF và synergizes with rapamycin in models of childhood sarcoma .107 .

Clin Orthop Relat Res .2010;468(10):2781–2788.

PMC free article]PubMed] Google Scholar]Tillander J., Hagberg K., Hagberg L., Brånemark R. Osseointegrated titanium implants for limb prostheses attachments : infectious complications .108 .

J Rehabil Res Dev .2009;46(3):331–344.

[PubMed] Google Scholar]Hagberg K., Brånemark R. One hundred patients treated with osseointegrated transfemoral amputation prostheses — rehabilitation perspective .109 .

Int J Radiat Oncol Biol Phys .2012;82(2):635–642.

PMC free article]PubMed] Google Scholar]Childs S.K., Kozak K.R., Friedmann A.M. Proton radiotherapy for parameningeal rhabdomyosarcoma : clinical outcomes & late effects .110 .

Int J Radiat Oncol Biol Phys .2012;82(3):1142–1148.

[PubMed] Google Scholar]Rombi B., DeLaney T.F., MacDonald S.M. Proton radiotherapy for pediatric Ewing’s sarcoma : initial clinical outcomes .111 .

Cancer J.2009;15(4):298–305.

[PubMed] Google Scholar]Merchant T.E. Proton beam therapy in pediatric oncology .112 .

Cancer Control .2008;15(1):21–37.

[PubMed] Google Scholar]Patel S., DeLaney T.F. Advanced-technology radiation therapy for bone sarcomas .113 .

Int J Radiat Oncol Biol Phys .2002;54(3):824–829.

[PubMed] Google Scholar]Miralbell R., Lomax A., Cella L., Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors .114 .

Int J Radiat Oncol Biol Phys .2009;74(3):732–739.

PMC free article]PubMed] Google Scholar]DeLaney T.F., Liebsch N.J., Pedlow F.X. Phase II study of high-dose photon / proton radiotherapy in the management of spine sarcomas .115 .

J Clin Oncol .2007;25(8):947–952.

[PubMed] Google Scholar]Timmerman R.D., Kavanagh B.D., Cho L.C., Papiez L., Xing L. Stereotactic body toàn thân radiation therapy in multiple organ sites .116 .

Neurosurgery .2009;64(2, suppl):A54–A59.

[PubMed] Google Scholar]Levine A.M., Coleman C., Horasek S. Stereotactic radiosurgery for the treatment of primary sarcomas và sarcoma metastases of the spine .117 .

Neurosurg Focus .2001;11(6):e7.

[PubMed] Google Scholar]Bilsky M.H., Yenice K., Lovelock M., Yamada J. Stereotactic intensity-modulation radiation therapy for vertebral body toàn thân và paraspinal tumors .

118 .